AMYRA Biotech AG is a leader in the development of innovative solutions to support and enhance the digestive capabilities of enzymes lining the small intestine. AMYRA’s Brush Border Enzyme Supplementation Technology (BBEST) pipeline addresses general health and nutrition, food sensitivities, and gastrointestinal diseases. The lead product in AMYRA’s BBEST pipeline, AMYNOPEP01, is the first and only synergistic combination of exopeptidases, enzymes specifically designed to completely digest protein fragments into easily absorbed amino acids. AMYRA is based in Basel, Switzerland.
Annual Revenue$1M to $5M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.